Industry
Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Loading...
Open
30.13
Mkt cap
970M
Volume
521K
High
30.55
P/E Ratio
12.86
52-wk high
42.29
Low
29.77
Div yield
N/A
52-wk low
28.87
Portfolio Pulse from
November 13, 2024 | 4:00 pm
Portfolio Pulse from
November 08, 2024 | 2:45 pm
Portfolio Pulse from
November 08, 2024 | 12:00 am
Portfolio Pulse from Benzinga Newsdesk
October 11, 2024 | 5:58 pm
Portfolio Pulse from Avi Kapoor
September 05, 2024 | 12:19 pm
Portfolio Pulse from Benzinga Insights
September 05, 2024 | 12:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.